Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Sudosalve Nappy Rash Treatment 0.15%w/w Cream

Active Ingredient:
ATC code: 
D08AC01
{info_black}
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 15 Apr 2025
1. Name of the medicinal product

Sudosalve nappy rash treatment 0.15%w/w cream

2. Qualitative and quantitative composition

Dibrompropamidine isetionate 0.15%w/w

For a full list of excipients, see section 6.1.

3. Pharmaceutical form

Cream

A smooth, white cream.

4. Clinical particulars
4.1 Therapeutic indications

Indications

(a) First aid dressing for minor burns, scalds, abrasions and other open injuries and their routine treatment.

(b) For the treatment of surface infections due to susceptible organisms, particularly in cases with penicillin resistant Staphylococci or certain Gramnegative bacilli.

(c) Treatment of ringworm of the scalp (Microsporum canis) and other superficial fungal infections.

(d) Treatment of pyodermias, including sycosis barbae.

(e) Treatment of otitis externa.

(f) Treatment of nappy rash.

4.2 Posology and method of administration

Adults: apply to the affected area, either directly or on a light dressing, two or three times a day.

Elderly and children: no specific recommendations.

For cutaneous use.

4.3 Contraindications

Sudosalve nappy rash treatment 0.15%w/w Cream should not be used in patients with known hypersensitivity to dibrompropamidine or any of the other ingredients.

4.4 Special warnings and precautions for use

Prolonged use may interfere with healing and cause skin necrosis in infants.

This medicine contains the following excipients:

• Methyl parahydroxybenzoate (E218) may cause allergic reactions (possibly delayed)

• Castor oil may cause skin reactions

• Cetostearyl alcohol may cause local skin reactions (eg. contact dermatitis).

4.5 Interaction with other medicinal products and other forms of interaction

None known

4.6 Fertility, pregnancy and lactation

There is no evidence of the drug's safety in human use nor is there any evidence from animal work that it is free from hazard. Avoid unless considered essential.

4.7 Effects on ability to drive and use machines

None.

4.8 Undesirable effects

There is always the possibility, although rare, of a sensitisation reaction or contact dermatitis occurring: in such an event, treatment should be discontinued immediately.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

The 25g tube of Sudosalve nappy rash treatment 0.15%w/w Cream contains 37.5mg of dibrompropamidine, the 30g contains 45mg and the 50g contains 75mg. No toxic effects are likely to occur even if the contents of a full tube are accidentally ingested. Similarly, the ingredients of the base are unlikely to have toxic effects in the quantities present.

5. Pharmacological properties
5.1 Pharmacodynamic properties

ATC code: D08AC01

Dibrompropamidine isetionate is an antibacterial agent active against pathogenic Streptococci and Staphylococci, including penicillin resistant strains, and has some activity against a number of Gram negative bacilli. Its antibacterial action is not inhibited by pus, blood or p-aminabenzoic acid. In addition, it has useful activity against certain species of pathogenic fungi. Sudosalve nappy rash treatment 0.15%w/w Cream is well tolerated and rarely gives rise to sensitisation reactions or contact dermatitis.

5.2 Pharmacokinetic properties

No data available.

5.3 Preclinical safety data

No relevant data.

6. Pharmaceutical particulars
6.1 List of excipients

Castor oil, virgin

Cetostearyl alcohol

Polyethylene glycol 600 monostearate

Methyl parahydroxybenzoate

Silicone MS Antifoam A

Purified water

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

36 months

6.4 Special precautions for storage

Store below 25°C.

6.5 Nature and contents of container

Collapsible aluminium internally lacquered tube with extended nozzle containing 25g, 30g or 50g cream. Polythene plug seal cap.

6.6 Special precautions for disposal and other handling

Not applicable.

7. Marketing authorisation holder

Teva UK Limited,

Ridings Point,

Whistler Drive,

Castleford,

WF10 5HX,

United Kingdom

8. Marketing authorisation number(s)

PL 00289/2629

9. Date of first authorisation/renewal of the authorisation

17/08/2009

10. Date of revision of the text

12/03/2025

Teva Pharma B.V.
Company image
Address
Field House, Station Approach, Harlow, Essex, CM20 2FB
WWW
Telephone
+44(0) 207 540 7000
Medical Information Direct Line
+44(0) 207 540 7117
Medical Information Fax
+44 (0) 207 000 1216
Stock Availability
0800 590 502
Medical Information e-mail
[email protected]